Skip to main content

Eloxx Pharmaceuticals, Inc.

ELOX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001035354

No open-market purchases or sales by Eloxx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $34.7M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Eloxx Pharmaceuticals, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of ELOX: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders4139−2
Shares16.1M16.5M+422.3K (+2.6%)
Value$26.0M$11.7M−$14.4M (−55.2%)

New holders (10)

Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to ELOX in Q4 2021
InstitutionSharesValue% of portfolio
Harel Insurance Investments & Financial Services Ltd.1,176,401$831.0K0.02%
Anson Funds Management LP553,652$391.0K0.05%
Virtu Financial LLC130,270$91.0K0.01%
Atom Investors LP113,151$80.0K0.02%
B. Riley Wealth Management, Inc.48,500$34.0K0.00%
Group One Trading, L.P.44,772$31.0K0.00%
Rafferty Asset Management, LLC26,072$18.0K0.00%
Two Sigma Securities, LLC17,499$12.0K0.00%
Tower Research Capital LLC (TRC)9,596$7.00K0.00%
National Bank of Canada6$00.00%

Sold out (12)

Institutions that held Eloxx Pharmaceuticals, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of ELOX in Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
Altium Capital Management LP1,118,000$1.82M
Natixis103,900$170.0K
Private Advisor Group, LLC32,510$52.0K
Goldman Sachs Group Inc27,588$45.0K
Meeder Asset Management Inc25,778$41.0K
Price T Rowe Associates Inc22,700$37.0K
ExodusPoint Capital Management, LP19,720$32.0K
Mesirow Financial Investment Management, Inc.18,894$31.0K
Sawtooth Solutions, LLC16,201$26.0K
Barclays PLC3,678$6.00K
FMR LLC338$1.00K
Brewin Dolphin Ltd15$24